



# **Headache Clinical Practice Guidelines**

## **Definition**

Headache is a common pain condition worldwide. It is important for physicians evaluating adult patients with acute headache to determine whether the condition is benign or if it indicates dangerous neurologic or systemic pathology. The most common types of headaches are tension-type headaches, migraines, and cluster headaches, which affect approximately 40, 10, and 1 percent of the adult population, respectively.

### **Assessment (History and Examination)** Figure 1. Quick reference algorithm from the Guideline for Primary Care Management of Headache in Adults Red flags Emergent (address immediately) Thunderclap onset Fever and meningismus Papilledema with focal signs or reduced LOC Acute glaucoma Urgent (address within hours to days) Temporal arteritis Papilledema (WITHOUT focal signs or reduced LOC) Relevant systemic illness Elderly patient: new headache with cognitive change Refer and investigate Possible indicators of secondary headache Aggravation by neck movement; abnormal neck examination findings (consider cervicogenic headache) Jaw symptoms; abnormal jaw examination findings (consider temporomandibular joint disorder) Unexplained focal signs Atypical headaches Unusual headache precipitants Unusual aura symptoms Onset after age 50 y Migraine ligraine Acute medications (Table 2) Monitor for medication overuse Prophylactic medication (Table 2) if -headache > 3 d/mo and acute medications are not effective OR -headache > 8 d/mo (risk of overuse) OR -disability despite acute medication 1 Headache with ≥2 of Medication overuse Nausca Light sensitivity Interference with activities Practice points: Migraine has been historically underdiagnosed Consider migraine diagnosis for recurring "sinus" headache ◆ Ergots, triptans, combination analgesies, or codeine or other opioids ≥ 10 d/mo Migraine Behavioural management Keep headache diary: record frequency, intensity, triggers, ≥10 d/mo OR Acetaminophen or NSAIDs ≥15 d/mo frequency, intensity, triggers, medication Adjust lifestyle factors: reduce caffeine, ensure regular exercise, avoid irregular or inadequate sleep or meals Develop stress management strategies: relaxation training, CBI, pacing activity, biofeedback > 15 d/mo Manage • Educate patient • Consider prophylactic medication • Provide an effective acute medication for severe attacks with limitations on frequency of use • Gradual withdrawal of opioids if used, or combination analgesic with opioid or barbiturate • Abrupt (or gradual) withdrawal of acetaminophen, NSAIDs, Headache with no nausea but ≥2 of Bilateral headache Nonpulsating pain Mild to moderate pain Not worsened by activity Tension-type headache Tension-type headache Acute medications (Table 3) Monitor for medication overuse Prophylactic medication (Table 3) if disability despite acute medication Uncommon headache syndromes II of Frequent headache Severe Brief (<3 h per attack) Unilateral (always same side) Ipsilateral eye redness, tearing, or restlessness during attacks Cluster headache or another trigeminal autonomic cephalalgia • Management primarily pharmacologic • Acute medication (Table 4) • Prophylactic medication (Table 4) • Early specialist referral recommended acetaminophen, NSAIDs. or triptans Unilateral (always same side) Continuous Dramatically responsive to indomethacin Hemicrania continua Headache continuous since onset New daily persistent headache • Specialist referral CBT—cognitive behavioural therapy, LOC—level of consciousness, NSAID—nonsteroidal anti-inflammatory drug. Adapted from Toward Optimized Practice.\*\*



cluster3Riyadh







# Management

A)						
TYPE	ACUTE MEDICATIO	NS				
First line	Ibuprofen 400 mg, ASA 1000 mg, naproxen sodium 500-550 mg, acetaminophen 1000 mg					
Second line	Triptans: oral sumatriptan 100 mg, rizatriptan 10 mg, almotriptan 12.5 mg, zolmitriptan 2.5 mg, eletriptan 40 mg, frovatriptan 2.5 mg, naratriptan 2.5 mg  • Subcutaneous sumatriptan 6 mg if the patient is vomiting early in the attack. Consider for attacks resistant to oral triptans  • Oral wafer: rizatriptan 10 mg or zolmitriptan 2.5 mg if fluid ingestion worsens nausea  • Nasal spray: zolmitriptan 5 mg or sumatriptan 20 mg if patient is nauseated  Antiemetics: domperidone 10 mg or metoclopramide 10 mg for nausea					
Third line	Naproxen sodium 500-550 mg in combination with a triptan					
Fourth line	Fixed-dose comb	ination analgesics (with c	odeine if necessary; not recon	nmended for routine use)		
B)		<del>78</del> */-				
PROPHYLACTIC MEDICATIONS	STARTING DOSE	TITRATION,* DAILY DOSE INCREASE	TARGET DOSE OR THERAPEUTIC RANGE <sup>+</sup>	NOTES		
First line				10.000/0000		
propranolol	20 mg twice daily	40 mg/wk	40-120 mg twice daily	Avoid in asthma		
metoprolol	50 mg twice daily	50 mg/wk	50-100 mg twice daily	Avoid in asthma		
nadolol	40 mg/d	20 mg/wk	80-160 mg/d	Avoid in asthma		
amitriptyline	10 mg at bedtime	10 mg/wk	10-100 mg at bedtime	Consider if patient has depression, anxiety, insomnia, or tension-type headache		
nortriptyline	10 mg at bedtime	10 mg/wk	10-100 mg at bedtime	Consider if patient has depression, anxiety, insomnia, or tension-type headache		
Second line						
topiramate	25 mg/d	25 mg/wk	50 mg twice daily	Consider as a first-line option if the patient is overweight		
candesartan	8 mg/d	8 mg/wk	16 mg/d	Few side effects; limited experience in prophylaxis		
gabapentin	300 mg/d	300 mg every 3-7 d	1200–1800 mg/d divided into 3 doses	Few drug interactions		
Other						
divalproex	250 mg/d	250 mg/wk	750-1500 mg/d divided into 2 doses	Avoid in pregnancy or when pregnancy is possible		
• pizotifen	0.5 mg/d	0.5 mg/wk	1-2 mg twice daily	Monitor for somnolence and weight gain		
onabotulinumtoxinA	155-195 units	No titration needed	155-195 units every 3 mo	For chronic migraine only (headache on ≥ 15 d/mo)		
flunarizine     venlafaxine	5-10 mg at bedtime 37.5 mg/d	No titration needed 37.5 mg/wk	10 mg at bedtime 150 mg/d	Avoid in patients with depression Consider for migraine in patients with depression		
Over the counter • magnesium citrate	300 mg twice daily	No titration needed	300 mg twice daily	Effectiveness might be limited; few side effects		
riboflavin	400 mg/d	No titration needed	400 mg/d	Effectiveness might be limited; few side effects		
• butterbur	75 mg twice daily	No titration needed	75 mg twice daily	Effectiveness might be limited; few side effects		
• coenzyme Q10	100 mg 3 times daily	No titration needed	100 mg 3 times daily	Effectiveness might be limited; few side effects		

ASA—acetylsalicylic acid.
\*Dosage can be increased every 2 wk to avoid side effects. For most drugs, slowly increase to the target dose; a therapeutic trial requires several months. The expected outcome is reduction not elimination of attacks.

†If the target dose is not tolerated, try a lower dose. If the medication is effective and tolerated, continue it for at least 6 mo. If several preventive

drugs fail, consider a specialist referral.

Adapted from Toward Optimized Practice.<sup>10</sup>

cluster3Riyadh











Table 3. Medications for tension-type headache				
MEDICATION	DOSE			
Acute				
lbuprofen	400 mg			
ASA	1000 mg			
Naproxen sodium	500-550 mg			
Acetaminophen	1000 mg			
Prophylactic				
First line				
<ul> <li>amitriptyline</li> </ul>	10-100 mg/d			
<ul> <li>nortriptyline</li> </ul>	10-100 mg/d			
Second line				
<ul><li>mirtazapine</li></ul>	30 mg/d			
<ul><li>venlafaxine</li></ul>	150 mg/d			
ASA—acetylsalicylic acid.				

Adapted from Toward Optimized Practice.10

**Table 4.** Medications for cluster headache: Consider early specialist referral.

MEDICATION	DOSE	
Acute		
Subcutaneous sumatriptan	6 mg	
Intranasal zolmitriptan	5 mg	
100% oxygen	12 L/min for 15 min through non-rebreathing mask	
Prophylactic*		
First line		
• verapamil	240–480 mg/d (higher doses might be required)	
Second line		
• lithium	900-1200 mg/d	
Other		
<ul><li>topiramate</li></ul>	100-200 mg/d	
<ul><li>melatonin</li></ul>	Up to 10 mg/d	

\*If the patient has more than 2 attacks daily, consider transitional therapy while verapamil is built up (eg, 60 mg of prednisone for 5 d, then reduced by 10 mg every 2 d until discontinued).

Adapted from Toward Optimized Practice.<sup>10</sup>






cluster3Riyadh




















MANAGEMENT





DIAGNOSTIC CRITERIA

TYPE





APPROVL						
	Name:	Position:	Signature:			
Prepared By:	Dr. Mohammed AlQahtani	FM Consultant				
Reviewed and Approved By:	Dr. Mansoor Allajhar Dr. Musa Althwayee Dr. Ahmed Al Zahrani Dr. Hajar Al Suma Dr. Ahlam Al Harbi	FM Consultants				

## Adopted from;

AAFP

**CHI Guidelines** 



